Philips maintains a Business Continuity Management System, which is aligned to, and certified against, the international standard for Business Continuity ISO 22301:2012. We are constantly reviewing precautionary measures based on WHO and national authority guidelines.
Despite the COVID-19 pandemic, Philips has been able to continue its business operations around the world. As expected, we are seeing decreased demand for our consumer product portfolio in the most affected regions, and increased demand for our professional healthcare portfolio.
Philips has a balanced manufacturing footprint across the globe, with manufacturing sites in North America, Latin America, Europe, and Asia, including several in China. In line with our business continuity system, we have implemented the relevant safety protocols in all our worldwide sites.
We are ramping up our production in China since the restart in February, 2020, where we are now above 80% capacity utilisation. To meet the increased demand for our professional healthcare products and solutions, across the globe we are in the process of increasing their production and roll-out. In particular, this relates to certain diagnostic imaging systems, patient monitors and ventilators – see below. We are working closely with our suppliers to secure materials supply to feed both our own manufacturing sites and our finished goods suppliers.